Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study Authors: Meijiao Zhou, Despina Ruessmann, Linda H. Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger Published: 2026 ABSTRACT BackgroundHyperkalemia is a common and potentially life-threatening complication among patients receiving maintenance hemodialysis (HD). Patiromer (Veltassa®) is an oral potassium binder with established potassium control efficacy in chronic kidney disease, but evidence in HD patients remains limited.MethodsWe conducted a retrospective, single-arm, cohort study of adult patients (n = 10,860) receiving in-center HD at Fresenius Kidney Care clinics who initiated patiromer between 2016 and 2022, comparing outcomes before (baseline: 3 months prior to initiation) and after initiation (up to 12 months of follow-up). Outcomes included changes in serum potassium (sK), treatment schedules, dosing patterns, and hospitalizations.ResultsAt baseline, mean age was 60 years, 58% were male, and mean sK was 5.60 ± 0.56 mEq/L. Following patiromer initiation, the proportion of patients achieving sK < 5.5 mEq/L increased from 35.6% to 69.9%. Mean sK decreased to 5.30 mEq/L at quarter 1 (Q1) and remained stable through Q4 (5.21 mEq/L). Mean sK reductions at Q4 were − 0.40, − 0.30, and − 0.21 mEq/L for patiromer doses of 8.4 g, 16.8 g, and 25.2 g once daily, respectively. Patiromer was most commonly prescribed once daily (55.9%) at 8.4 g (91.2%), and dose titrations were infrequent. Use of 1 mEq/L potassium dialysate declined from 17.2% to 11.0%. From baseline to 12 months, all-cause hospitalization rate decreased from 1.77 to 1.68 events per person-year (p = 0.004), while hyperkalemia-related hospitalizations declined from 0.35 to 0.20 (p < 0.0001). Serum calcium, sodium, phosphorus, and magnesium remained stable.ConclusionsIn this large real-world cohort, lower serum potassium levels were observed following patiromer initiation over 12 months, along with stable electrolyte profiles and a low need for dose adjustments. Reductions in hospitalization rates were also observed over time but should be interpreted cautiously given the single-arm, retrospective design without a control group. These findings support the clinical utility of patiromer for chronic hyperkalemia management in HD patients.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05129-z. Background Elevated serum potassium (sK), hyperkalemia, is a potentially life-threatening electrolyte disturbance that can lead to arrhythmias and sudden death [1]. Hyperkalemia presents a frequent and clinically significant complication in patients with end-stage renal disease (ESRD) undergoing chronic hemodialysis (HD) [2, 3]. Additionally, hyperkalemia has been associated with higher all-cause and cardiovascular mortality in patients on maintenance HD [3]. Hyperkalemia is particularly common after the long interdialytic interval, when prevalence may be substantially higher than after shorter intervals [4]. Further, the rapid lowering of sK levels in patients with high pre-dialysis sK through the use of 1 mEq/L potassium dialysate concentrations (1 K bath) has been associated with higher mortality when compared to higher potassium bath concentrations [5, 6]. Alternative strategies employed in the management of hyperkalemia include reducing dietary potassium intake and limiting the use of medications that may exacerbate hyperkalemia, such as renin–angiotensin–aldosterone system inhibitors (RAASi) [7, 8]. Historically, there have been few pharmacologic interventions to manage hyperkalemia in patients receiving chronic HD. Patiromer is a non-absorbed polymer that facilitates sodium-free exchange of potassium for calcium in the colon, thereby facilitating potassium removal and lowering sK levels in patients with hyperkalemia [9]. It was approved for the treatment of hyperkalemia by the United States Food and Drug Administration in 2015 and by the European Medicines Agency in 2017 [10, 11]. The safety and efficacy of patiromer in managing hyperkalemia have previously been established in patients with chronic kidney disease (CKD) receiving concomitant RAASi, where it was shown to reduce sK in a follow-up of 52 weeks [12, 13]. While the use of patiromer to manage hyperkalemia in CKD patients has been well documented, evidence concerning its use in ESRD patients receiving HD treatment is limited. Few randomized controlled studies have evaluated the use of patiromer in patients on HD [14, 15]. While there has been real-world evidence concerning the use of patiromer in HD patients to manage hyperkalemia [16, 17], evidence on its use, treatment schedules, and dosing in clinical practice is needed in large generalizable cohorts. Despite established potassium-lowering effects, the clinical role of patiromer in hemodialysis populations remains insufficiently characterized in routine practice. In particular, there is limited evidence describing how patiromer is implemented in real-world dialysis care, including treatment schedules, dose prescriptions and adjustments over time, and whether potassium control is maintained longitudinally under heterogeneous prescribing patterns. In addition, real-world data describing associated changes in related clinical management parameters in large, generalizable dialysis cohorts remain scarce. To characterize the use of patiromer in real-world practice, we conducted a retrospective, single-arm cohort study of adult patients receiving maintenance HD at Fresenius Kidney Care (FKC) clinics. The primary aim was to describe changes in sK levels before and after patiromer initiation over a 12-month follow-up period. Secondary objectives included characterizing real-world prescribing patterns and associated changes in clinically relevant lab parameters, and hospitalization outcomes to better understand how patiromer is used in clinical practice in the United States. We expected to observe changes in sK levels following patiromer initiation in routine clinical practice. Methods Study design and data source This descriptive retrospective single-arm cohort study evaluated the real-world effectiveness of patiromer in adult patients receiving in-center HD treatment, comparing outcomes before and after patiromer initiation. De-identified demographic, clinical, and prescription data were extracted from the FKC data warehouse and the FreseniusRx pharmacy database. This study was reviewed by an independent review board (New England Independent Review Board/WCG IRB, Needham, MA, USA; WCG IRB Work Order # 1-1761981-1), and was granted an exempt status under the common rule and applicable guidance because of its purely observational nature and the use of de-identified data. Study population and study periods Adult (18–89 years) in-center HD patients were included if they were prescribed patiromer monotherapy as a part of routine clinical care between January 2016 and December 2022, with no patiromer use in the year prior to initiation, and had been on HD for at least 90 days before initiating patiromer. Eligible patients were prescribed thrice weekly HD and had at least one sK measurement both within 91 days prior to patiromer initiation and during patiromer treatment. For each patient, the first patiromer treatment date during the study period was defined as the index date. Patients were followed for up to 12 months after the index date or until patiromer discontinuation, kidney transplant, kidney function recovery, discharge from FKC, or death. Observation periods were divided into consecutive 91-day intervals. The 3 months preceding patiromer prescription (-3 M, -2 M, and − 1 M) were considered Quarter One baseline (-1Q), and the 12 months following patiromer initiation (M1–M12) were defined as Quarters One through Four follow-up (Q1–Q4). Study outcomes were assessed by comparing values during the baseline period (-1Q) with those observed during the follow-up period. Study outcomes The primary outcome was changes in sK levels from baseline to follow-up over 12 months. Secondary outcomes included descriptive assessments of treatment utilization patterns (patiromer dosing strength, treatment schedules), and other lab parameters of interest (electrolytes, dialysate composition, mineral bone disorder parameters, nutritional and clearance parameters). Use of a 1 mEq/L potassium dialysate (1 K bath) each quarter was defined as receipt of at least one dialysis treatment with a 1 K bath during the specified time period. Serum calcium, magnesium, sodium, phosphorus, and iPTH were also monitored to assess potential off-target electrolyte and mineral effects in this hemodialysis population. Hypokalemia and hypomagnesemia occurrence were also reported. Hospitalization and mortality rates across the study period were described to provide clinical context. Hospitalizations occurring early in the week (Sunday and Monday), when a longer interdialytic interval is typically experienced, were also described. Statistical analysis Baseline characteristics are presented as mean ± standard deviation (SD) for continuous variables and as counts (percentage) for categorical variables. Arithmetic means of continuous data were calculated monthly and/or quarterly. Hospitalization rates and their corresponding 95% confidence intervals (CI) were calculated and compared between the baseline and follow-up periods using Poisson regression. Subgroup analyses were conducted descriptively to assess consistency of serum potassium trends across clinically relevant patient subgroups, including drug strength, baseline serum potassium levels, RAAS inhibitor use, and congestive heart failure status. Given the single-arm retrospective design, all analyses were descriptive in nature and no causal inference was intended. A sensitivity analysis was performed among patients prescribed patiromer for the full 12-month period. All analyses were conducted with SAS (SAS® Enterprise Guide® 8.3, SAS Institute Inc., Cary, NC, USA). Results Patient characteristics and clinical parameters Of the 13,004 FKC adult HD patients prescribed patiromer monotherapy between January 2016 and December 2022, 10,860 patients met the study criteria and were included in the analysis (Fig. 1). Mean age at baseline was approximately 60 ± 13.4 years, and 58% of the patients were male (Table 1). Patients had a mean dialysis vintage of 58 ± 49.4 months at the time of patiromer initiation, and 67% of all patients had diabetes mellitus while 21% had CHF. Additionally, 92% of patients had no prior prescription of potassium binders recorded before patiromer initiation. Fig. 1Patient disposition. Abbreviations: FKC, Fresenius Kidney Care; HD, hemodialysis Patient disposition. Abbreviations: FKC, Fresenius Kidney Care; HD, hemodialysis Table 1Patient characteristics at baseline*Baseline characteristicsOverall patients (n = 10860)Age, years60.4 ± 13.4Dialysis vintage, months58.0 ± 49.4Post-dialysis BMI, kg/m228.7 ± 7.4SexMale6341 (58.4%)Female4519 (41.6%)RaceWhite7234 (66.6%)Black/African American2596 (23.9%)Asian/Pacific Islander446 (4.1%)Other146 (1.3%)Missing/Unknown438 (4.0%)EthnicityHispanic2737 (25.2%)Non-Hispanic7638 (70.3%)Missing/Unknown485 (4.5%)Primary cause of renal failureDiabetes mellitus5597 (51.5%)Hypertension2809 (25.9%)Glomerulonephritis716 (6.6%)Polycystic kidney297 (2.7%)Other1436 (13.2%)Missing/Unknown5 (0.1%)ComorbiditiesDiabetes mellitus7271 (67.0%)Congestive heart failure2224 (20.5%)Non-patiromer potassium binder (PB) at baselineNo PB recorded9997 (92.1%)PB recorded863 (7.9%)†*Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated† Among n = 863 patients, 564 (65.4%) patients were prescribed sodium polystyrene sulfonate (SPS), 291 (33.7%) were prescribed sodium zirconium cyclosilicate (SZC), and 8 (0.9%) were switched between SZC and SPSAbbreviations: BMI, body mass index; PB, potassium binder Table 1Patient characteristics at baseline*Baseline characteristicsOverall patients (n = 10860)Age, years60.4 ± 13.4Dialysis vintage, months58.0 ± 49.4Post-dialysis BMI, kg/m228.7 ± 7.4SexMale6341 (58.4%)Female4519 (41.6%)RaceWhite7234 (66.6%)Black/African American2596 (23.9%)Asian/Pacific Islander446 (4.1%)Other146 (1.3%)Missing/Unknown438 (4.0%)EthnicityHispanic2737 (25.2%)Non-Hispanic7638 (70.3%)Missing/Unknown485 (4.5%)Primary cause of renal failureDiabetes mellitus5597 (51.5%)Hypertension2809 (25.9%)Glomerulonephritis716 (6.6%)Polycystic kidney297 (2.7%)Other1436 (13.2%)Missing/Unknown5 (0.1%)ComorbiditiesDiabetes mellitus7271 (67.0%)Congestive heart failure2224 (20.5%)Non-patiromer potassium binder (PB) at baselineNo PB recorded9997 (92.1%)PB recorded863 (7.9%)†*Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated† Among n = 863 patients, 564 (65.4%) patients were prescribed sodium polystyrene sulfonate (SPS), 291 (33.7%) were prescribed sodium zirconium cyclosilicate (SZC), and 8 (0.9%) were switched between SZC and SPSAbbreviations: BMI, body mass index; PB, potassium binder Patient characteristics at baseline* *Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated † Among n = 863 patients, 564 (65.4%) patients were prescribed sodium polystyrene sulfonate (SPS), 291 (33.7%) were prescribed sodium zirconium cyclosilicate (SZC), and 8 (0.9%) were switched between SZC and SPS Abbreviations: BMI, body mass index; PB, potassium binder At baseline, the mean sK was 5.60 ± 0.56 mEq/L (Table 2). Following patiromer initiation, mean sK decreased and remained stable across each quarterly interval, with values of 5.30 ± 0.55 mEq/L at Q1, 5.24 ± 0.55 mEq/L at Q2, 5.22 ± 0.55 mEq/L at Q3, and 5.21 ± 0.55 mEq/L at Q4. This reduction in mean sK was consistent when calculated monthly (Fig. 2). At Q4, 69.9% of patients had achieved sK < 5.5 mEq/L compared to 35.6% at baseline (Table 2). Table 2Comparison of quarterly changes in prescription, laboratory and clinical parameters, and health outcomes: baseline (-1Q) and 1 year follow-up (Q1-Q4)*BaselineFollow-up–1Q; refQ1Q2Q3Q4Patients on patiromer, n10,860888474816348Patients discontinued patiromer1976 (18.2%)1403 (15.8%)1133 (15.1%)968 (15.2%)Patiromer8.4 g packets / day/0.99 ± 0.531.01 ± 0.561.03 ± 0.581.04 ± 0.59Changes in patiromer packets†patients up-titrated501 (6.6%)396 (6.3%)305 (5.7%)patients down-titrated380 (5.0%)282 (4.5%)239 (4.5%)patients no changes6744 (88.4%)5643 (89.3%)4824 (89.9%)Lab parametersPatients with serum potassium (sK) values, n10,86010,854869473236238sK, mEq/L5.60 ± 0.565.30 ± 0.555.24 ± 0.555.22 ± 0.555.21 ± 0.55sK < 5.5 mEq/L, %35.662.966.567.969.9Hypokalemia (sK < 3.5 mEq/L), %0.080.110.080.050.13Serum calcium, mg/dL8.93 ± 0.598.95 ± 0.608.96 ± 0.608.96 ± 0.608.96 ± 0.59Serum sodium, mEq/L136.8 ± 3136.9 ± 3137.0 ± 3137.0 ± 3137.0 ± 3Serum phosphorus, mg/dL5.98 ± 1.665.88 ± 1.695.81 ± 1.665.78 ± 1.675.77 ± 1.65Serum calcium x phosphorus product < 4.4 mmol2/L2, %58.760.661.862.762.8Serum magnesium, mg/dL2.45 ± 0.402.41 ± 0.392.40 ± 0.382.39 ± 0.382.38 ± 0.38Hypomagnesemia (sMg < 1.8 mg/dL), %2.633.183.013.143.05iPTH, pg/mL512 ± 433503 ± 434506 ± 436507 ± 433511 ± 445Dialysate prescriptionPotassium, mEq/L1.99 ± 0.251.97 ± 0.241.99 ± 0.231.99 ± 0.231.99 ± 0.22Patients with one or more treatments with 1 mEq/L potassium prescribed (potassium bath), %17.216.812.711.311.0Calcium, mEq/L2.46 ± 0.222.46 ± 0.222.46 ± 0.222.46 ± 0.222.46 ± 0.22Sodium, mEq/L137.3 ± 1137.2 ± 1137.2 ± 1137.2 ± 1137.2 ± 1Magnesium, mEq/L1.00 ± 0.021.00 ± 0.021.00 ± 0.021.00 ± 0.021.00 ± 0.02Nutritional and clearance parametersPre-HD body weight, Kg83.8 ± 23.084.0 ± 23.084.2 ± 23.084.2 ± 23.084.3 ± 22.9Post-HD body weight, Kg81.2 ± 22.581.4 ± 22.581.7 ± 22.681.7 ± 22.581.8 ± 22.4Interdialytic weight gain, kg2.57 ± 0.942.52 ± 0.962.51 ± 0.962.49 ± 0.962.49 ± 0.94Serum albumin, g/dL3.89 ± 0.343.88 ± 0.353.89 ± 0.343.90 ± 0.353.90 ± 0.34Equilibrated nPCR, g/kg/day1.02 ± 0.231.01 ± 0.231.00 ± 0.231.00 ± 0.231.00 ± 0.23Single-Pool nPCR, g/kg/day1.10 ± 0.251.09 ± 0.261.08 ± 0.261.08 ± 0.261.08 ± 0.25eKt/V1.47 ± 0.261.48 ± 0.271.49 ± 0.271.49 ± 0.261.49 ± 0.26spKt/V1.70 ± 0.301.71 ± 0.301.72 ± 0.301.72 ± 0.291.72 ± 0.30Systolic blood pressure (SBP)Pre-HD SBP, mmHg151 ± 19151 ± 19151 ± 19150 ± 20150 ± 20Post-HD SBP, mmHg140 ± 18139 ± 18140 ± 19140 ± 19140 ± 19Comedication use‡RAAS inhibitor (ACEi, ARB, direct renin inhibitor)4032 (37.1%)3874 (35.7%)3127 (35.2%)2628 (35.1%)2204 (34.7%)MRAs121 (1.1%)115 (1.1%)89 (1%)70 (0.9%)46 (0.7%)Diuretics2768 (25.5%)2675 (24.6%)2119 (23.9%)1702 (22.8%)1399 (22.0%)Beta-blockers7301 (67.2%)7370 (67.9%)6037 (68.0%)5064 (67.7%)4328 (68.2%)Phosphate binders9817 (90.4%)10,044 (92.5%)8257 (92.9%)6977 (93.3%)5949 (93.7%)HD prescriptionFrequency, days/week2.99 ± 0.042.99 ± 0.032.99 ± 0.042.99 ± 0.042.99 ± 0.05Treatment time, mins228 ± 26228 ± 26228 ± 26228 ± 25228 ± 25HD deliveryFrequency, days/week2.81 ± 0.292.81 ± 0.312.80 ± 0.322.80 ± 0.322.81 ± 0.32Treatment time, mins223 ± 27223 ± 27223 ± 28223 ± 27223 ± 27Delivered average blood flow rate, mL/min411 ± 50412 ± 49413 ± 49413 ± 49413 ± 49Delivered average dialysate flow rate, mL/min703 ± 93703 ± 95701 ± 97700 ± 99697 ± 100Vascular access typeFistula6649 (61.5%)6854 (63.4%)5782 (65.7%)4928 (66.5%)4227 (67.1%)Graft1693 (15.6%)1744 (16.1%)1489 (16.9%)1282 (17.3%)1091 (17.3%)Catheter1717 (15.9%)1554 (14.4%)1104 (12.5%)866 (11.7%)698 (11.1%)Catheter and fistula497 (4.6%)397 (3.7%)258 (2.9%)201 (2.7%)159 (2.5%)Catheter and graft225 (2.1%)223 (2.1%)153 (1.7%)119 (1.6%)100 (1.6%)Fistula and graft23 (0.2%)32 (0.3%)19 (0.2%)12 (0.2%)17 (0.3%)Catheter, fistula and graft14 (0.1%)9 (0.1%)1 (0.01%)6 (0.1%)5 (0.1%)Dialyzer typeOptiflux F160NRe2783 (25.6%)2678 (24.7%)2120 (23.9%)1757 (23.6%)1490 (23.5%)Optiflux F180NRe7476 (68.8%)7555 (69.6%)6202 (70.1%)5231 (70.1%)4447 (70.2%)Optiflux F200NRe338 (3.1%)358 (3.3%)298 (3.4%)262 (3.5%)218 (3.4%)Optiflux F250NRe123 (1.1%)128 (1.2%)108 (1.2%)96 (1.3%)86 (1.4%)Others139 (1.3%)140 (1.3%)125 (1.4%)112 (1.5%)94 (1.5%)*Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated† The calculation did not include patients with missing treatment schedules (as directed, single dose, or missing)‡ Comedication use: medications prescribed at the time patiromer was initiatedAbbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; HD, hemodialysis; iPTH, intact parathyroid hormone; MRA, mineralocorticoid receptor antagonists; nPCR, normalized protein catabolic rate; RAASi, renin–angiotensin–aldosterone system inhibitors; sK, serum potassium; SBP, systolic blood pressure; sp, single-pool Table 2Comparison of quarterly changes in prescription, laboratory and clinical parameters, and health outcomes: baseline (-1Q) and 1 year follow-up (Q1-Q4)*BaselineFollow-up–1Q; refQ1Q2Q3Q4Patients on patiromer, n10,860888474816348Patients discontinued patiromer1976 (18.2%)1403 (15.8%)1133 (15.1%)968 (15.2%)Patiromer8.4 g packets / day/0.99 ± 0.531.01 ± 0.561.03 ± 0.581.04 ± 0.59Changes in patiromer packets†patients up-titrated501 (6.6%)396 (6.3%)305 (5.7%)patients down-titrated380 (5.0%)282 (4.5%)239 (4.5%)patients no changes6744 (88.4%)5643 (89.3%)4824 (89.9%)Lab parametersPatients with serum potassium (sK) values, n10,86010,854869473236238sK, mEq/L5.60 ± 0.565.30 ± 0.555.24 ± 0.555.22 ± 0.555.21 ± 0.55sK < 5.5 mEq/L, %35.662.966.567.969.9Hypokalemia (sK < 3.5 mEq/L), %0.080.110.080.050.13Serum calcium, mg/dL8.93 ± 0.598.95 ± 0.608.96 ± 0.608.96 ± 0.608.96 ± 0.59Serum sodium, mEq/L136.8 ± 3136.9 ± 3137.0 ± 3137.0 ± 3137.0 ± 3Serum phosphorus, mg/dL5.98 ± 1.665.88 ± 1.695.81 ± 1.665.78 ± 1.675.77 ± 1.65Serum calcium x phosphorus product < 4.4 mmol2/L2, %58.760.661.862.762.8Serum magnesium, mg/dL2.45 ± 0.402.41 ± 0.392.40 ± 0.382.39 ± 0.382.38 ± 0.38Hypomagnesemia (sMg < 1.8 mg/dL), %2.633.183.013.143.05iPTH, pg/mL512 ± 433503 ± 434506 ± 436507 ± 433511 ± 445Dialysate prescriptionPotassium, mEq/L1.99 ± 0.251.97 ± 0.241.99 ± 0.231.99 ± 0.231.99 ± 0.22Patients with one or more treatments with 1 mEq/L potassium prescribed (potassium bath), %17.216.812.711.311.0Calcium, mEq/L2.46 ± 0.222.46 ± 0.222.46 ± 0.222.46 ± 0.222.46 ± 0.22Sodium, mEq/L137.3 ± 1137.2 ± 1137.2 ± 1137.2 ± 1137.2 ± 1Magnesium, mEq/L1.00 ± 0.021.00 ± 0.021.00 ± 0.021.00 ± 0.021.00 ± 0.02Nutritional and clearance parametersPre-HD body weight, Kg83.8 ± 23.084.0 ± 23.084.2 ± 23.084.2 ± 23.084.3 ± 22.9Post-HD body weight, Kg81.2 ± 22.581.4 ± 22.581.7 ± 22.681.7 ± 22.581.8 ± 22.4Interdialytic weight gain, kg2.57 ± 0.942.52 ± 0.962.51 ± 0.962.49 ± 0.962.49 ± 0.94Serum albumin, g/dL3.89 ± 0.343.88 ± 0.353.89 ± 0.343.90 ± 0.353.90 ± 0.34Equilibrated nPCR, g/kg/day1.02 ± 0.231.01 ± 0.231.00 ± 0.231.00 ± 0.231.00 ± 0.23Single-Pool nPCR, g/kg/day1.10 ± 0.251.09 ± 0.261.08 ± 0.261.08 ± 0.261.08 ± 0.25eKt/V1.47 ± 0.261.48 ± 0.271.49 ± 0.271.49 ± 0.261.49 ± 0.26spKt/V1.70 ± 0.301.71 ± 0.301.72 ± 0.301.72 ± 0.291.72 ± 0.30Systolic blood pressure (SBP)Pre-HD SBP, mmHg151 ± 19151 ± 19151 ± 19150 ± 20150 ± 20Post-HD SBP, mmHg140 ± 18139 ± 18140 ± 19140 ± 19140 ± 19Comedication use‡RAAS inhibitor (ACEi, ARB, direct renin inhibitor)4032 (37.1%)3874 (35.7%)3127 (35.2%)2628 (35.1%)2204 (34.7%)MRAs121 (1.1%)115 (1.1%)89 (1%)70 (0.9%)46 (0.7%)Diuretics2768 (25.5%)2675 (24.6%)2119 (23.9%)1702 (22.8%)1399 (22.0%)Beta-blockers7301 (67.2%)7370 (67.9%)6037 (68.0%)5064 (67.7%)4328 (68.2%)Phosphate binders9817 (90.4%)10,044 (92.5%)8257 (92.9%)6977 (93.3%)5949 (93.7%)HD prescriptionFrequency, days/week2.99 ± 0.042.99 ± 0.032.99 ± 0.042.99 ± 0.042.99 ± 0.05Treatment time, mins228 ± 26228 ± 26228 ± 26228 ± 25228 ± 25HD deliveryFrequency, days/week2.81 ± 0.292.81 ± 0.312.80 ± 0.322.80 ± 0.322.81 ± 0.32Treatment time, mins223 ± 27223 ± 27223 ± 28223 ± 27223 ± 27Delivered average blood flow rate, mL/min411 ± 50412 ± 49413 ± 49413 ± 49413 ± 49Delivered average dialysate flow rate, mL/min703 ± 93703 ± 95701 ± 97700 ± 99697 ± 100Vascular access typeFistula6649 (61.5%)6854 (63.4%)5782 (65.7%)4928 (66.5%)4227 (67.1%)Graft1693 (15.6%)1744 (16.1%)1489 (16.9%)1282 (17.3%)1091 (17.3%)Catheter1717 (15.9%)1554 (14.4%)1104 (12.5%)866 (11.7%)698 (11.1%)Catheter and fistula497 (4.6%)397 (3.7%)258 (2.9%)201 (2.7%)159 (2.5%)Catheter and graft225 (2.1%)223 (2.1%)153 (1.7%)119 (1.6%)100 (1.6%)Fistula and graft23 (0.2%)32 (0.3%)19 (0.2%)12 (0.2%)17 (0.3%)Catheter, fistula and graft14 (0.1%)9 (0.1%)1 (0.01%)6 (0.1%)5 (0.1%)Dialyzer typeOptiflux F160NRe2783 (25.6%)2678 (24.7%)2120 (23.9%)1757 (23.6%)1490 (23.5%)Optiflux F180NRe7476 (68.8%)7555 (69.6%)6202 (70.1%)5231 (70.1%)4447 (70.2%)Optiflux F200NRe338 (3.1%)358 (3.3%)298 (3.4%)262 (3.5%)218 (3.4%)Optiflux F250NRe123 (1.1%)128 (1.2%)108 (1.2%)96 (1.3%)86 (1.4%)Others139 (1.3%)140 (1.3%)125 (1.4%)112 (1.5%)94 (1.5%)*Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated† The calculation did not include patients with missing treatment schedules (as directed, single dose, or missing)‡ Comedication use: medications prescribed at the time patiromer was initiatedAbbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; HD, hemodialysis; iPTH, intact parathyroid hormone; MRA, mineralocorticoid receptor antagonists; nPCR, normalized protein catabolic rate; RAASi, renin–angiotensin–aldosterone system inhibitors; sK, serum potassium; SBP, systolic blood pressure; sp, single-pool Comparison of quarterly changes in prescription, laboratory and clinical parameters, and health outcomes: baseline (-1Q) and 1 year follow-up (Q1-Q4)* *Data are presented as mean ± SD for continuous variables or n (%) for categorical variables, unless otherwise indicated † The calculation did not include patients with missing treatment schedules (as directed, single dose, or missing) ‡ Comedication use: medications prescribed at the time patiromer was initiated Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; HD, hemodialysis; iPTH, intact parathyroid hormone; MRA, mineralocorticoid receptor antagonists; nPCR, normalized protein catabolic rate; RAASi, renin–angiotensin–aldosterone system inhibitors; sK, serum potassium; SBP, systolic blood pressure; sp, single-pool Fig. 2Comparison of monthly changes in serum potassium (n = 10860) Comparison of monthly changes in serum potassium (n = 10860) Hypokalemia (< 3.5 mEq/L) was rare at baseline (0.08%) and remained low throughout follow-up (Q1: 0.11%; Q2: 0.08%; Q3: 0.05%; Q4: 0.13%). Throughout the study period, serum calcium and sodium concentrations remained stable. Mean serum calcium was 8.93 ± 0.59 mg/dL at baseline and ranged between 8.95 and 8.96 mg/dL during follow-up. Mean serum sodium was 136.8 ± 3.0 mEq/L at baseline and remained at approximately 137 mEq/L throughout the 12-month follow-up. Other serum electrolytes remained stable with slight decreases in serum phosphorus (5.98 ± 1.66 mg/dL at baseline to 5.77 ± 1.65 mg/dL at Q4) and serum magnesium (2.45 ± 0.40 mg/dL at baseline to 2.38 ± 0.38 mg/dL at Q4) concentrations observed. Hypomagnesemia (< 1.8 mg/dL) occurred in 2.63% of patients at baseline and ranged from 3.01 to 3.18% across follow-up quarters. Patiromer dosing remained stable over the follow-up period with 88.4%, 89.3%, and 89.9% of patients receiving no up-titrations or down-titrations to their dosing in Q2, Q3, and Q4, respectively. The use of comedications (i.e., medications prescribed at the time patiromer was initiated) such as RAASi, mineralocorticoid receptor antagonists, diuretics (high ceiling diuretic, potassium sparing diuretic, low ceiling nonthiazide, and low ceiling thiazide), beta-blockers, and phosphate binders also remained stable throughout the follow-up period (Table 2). The percentage of patients prescribed at least one 1 K bath decreased from 17.2% at baseline to 11.0% at Q4, and dialysate electrolyte concentrations (Potassium, Calcium, Sodium, and Magnesium) remained stable throughout the follow-up period. Patiromer discontinuations occurred gradually, with 18.2%, 15.8%, 15.1%, and 15.2% of patients discontinuing treatment in Q1, Q2, Q3, and Q4, respectively. Of the patients who were prescribed patiromer for 12 months (n = 5380), 69.8% achieved sK < 5.5 mEq/L, compared to 36.7% at baseline (Supplemental Table 1). Hospitalization and mortality rates At baseline, the all-cause hospitalization rate was 1.77 events per person-year (95% CI, 1.72–1.82), which decreased to 1.68 (95% CI, 1.65–1.71) during follow-up (p = 0.004) (Table 3). Hospitalizations due to hyperkalemia also experienced a reduction, declining from 0.35 (95% CI, 0.33–0.37) events per person-year at baseline to 0.20 (95% CI, 0.19–0.21) (p < 0.0001) during follow-up. Additionally, hospitalizations related to fluid overload demonstrated a modest reduction from 0.16 (95% CI, 0.14–0.17) events per person-year at baseline to 0.14 (95% CI, 0.13–0.14) (p = 0.006). We further explored hospital admissions occurring on Sunday and Monday. Overall, 38.6% and 37.8% of hospital admissions occurred on Sunday and Monday during baseline and follow-up, respectively. Fluid-overload hospital admissions and hyperkalemia hospital admissions were common during Sunday and Monday at baseline, with 40.3% and 41.9% occurring on Sunday and Monday during baseline and 38.2% and 38.8% during follow-up, respectively. The all-cause mortality rate during the follow-up period was 154 deaths per 1,000 person-years (95% CI, 146–163). Table 3Hospitalization and mortality rates across the study periodOutcomeBaselineFollow-upP valueHospitalization*All-cause hospitalization rate1.77 (1.72, 1.82)1.68 (1.65, 1.71)0.004Hospitalization rate due to hyperkalemia0.35 (0.33, 0.37)0.20 (0.19, 0.21)< 0.0001Hospitalization rate due to fluid overload0.16 (0.14, 0.17)0.14 (0.13, 0.14)0.006Death (patients dead during FU)Mortality rate (per 1000 person-years)/154 (146, 163)/*Hospitalization rates were expressed as per person-year. Data are presented as mean (95% CI)Abbreviations: CI, confidence interval; FU, follow-up Table 3Hospitalization and mortality rates across the study periodOutcomeBaselineFollow-upP valueHospitalization*All-cause hospitalization rate1.77 (1.72, 1.82)1.68 (1.65, 1.71)0.004Hospitalization rate due to hyperkalemia0.35 (0.33, 0.37)0.20 (0.19, 0.21)< 0.0001Hospitalization rate due to fluid overload0.16 (0.14, 0.17)0.14 (0.13, 0.14)0.006Death (patients dead during FU)Mortality rate (per 1000 person-years)/154 (146, 163)/*Hospitalization rates were expressed as per person-year. Data are presented as mean (95% CI)Abbreviations: CI, confidence interval; FU, follow-up Hospitalization and mortality rates across the study period *Hospitalization rates were expressed as per person-year. Data are presented as mean (95% CI) Abbreviations: CI, confidence interval; FU, follow-up Patiromer treatment schedules and dosing The most frequently recorded treatment schedules for the first prescription of patiromer were once daily (55.9%), as directed (12.3%), and every other day (6.7%) (Table 4). The most common dose of patiromer for the first prescription was 8.4 g (91.2%), followed by 16.8 g (7.8%) and 25.2 g (1.0%) (Table 4). Table 4Description of first patiromer prescription (n = 10860)Patient number, n (%) Drug strength 8.4 g9899 (91.2%)16.8 g851 (7.8%)25.2 g109 (1.0%)Missing1 (0.01%)Treatment scheduleAs directed1334 (12.3%)Single dose238 (2.2%)Four times a day13 (0.1%)Three times a day17 (0.2%)Twice a day99 (0.9%)Once a day6070 (55.9%)Every other day724 (6.7%)Three times a week431 (4.0%)Every three days10 (0.1%)Twice a week201 (1.9%)Once a week199 (1.8%)Every three months6 (0.1%)Missing1518 (14.0%) Table 4Description of first patiromer prescription (n = 10860)Patient number, n (%) Drug strength 8.4 g9899 (91.2%)16.8 g851 (7.8%)25.2 g109 (1.0%)Missing1 (0.01%)Treatment scheduleAs directed1334 (12.3%)Single dose238 (2.2%)Four times a day13 (0.1%)Three times a day17 (0.2%)Twice a day99 (0.9%)Once a day6070 (55.9%)Every other day724 (6.7%)Three times a week431 (4.0%)Every three days10 (0.1%)Twice a week201 (1.9%)Once a week199 (1.8%)Every three months6 (0.1%)Missing1518 (14.0%) Description of first patiromer prescription (n = 10860) Among patients who were prescribed once-daily patiromer, serum potassium declined from baseline across all dose strengths, accompanied by increased proportions achieving sK < 5.5 mEq/L. Mean sK reductions from baseline to Q4 were − 0.40 (5.61 ± 0.55 to 5.21 ± 0.55 mEq/L), − 0.30 (5.70 ± 0.54 to 5.40 ± 0.55 mEq/L), and − 0.21 (5.74 ± 0.56 to 5.53 ± 0.51 mEq/L) mEq/L for patiromer doses of 8.4 g, 16.8 g, and 25.2 g once daily, respectively. Reductions appeared more pronounced in the 8.4 g group; however, these differences should be interpreted in the context of baseline variation and smaller sample sizes in the higher-dose cohorts (Table 5). Table 5Serum potassium changes by drug strength among patients who were prescribed patiromer once a dayBaselineFollow-up–1Q; refQ1Q2Q3Q4 Drug strength of 8.4 g (n = 5452) Patients with serum potassium (sK) values, n54525447433436193070sK, mEq/L5.61 ± 0.555.31 ± 0.555.24 ± 0.555.24 ± 0.565.21 ± 0.55sK < 5.5 mEq/L, %34.762.367.066.870.1 Drug strength of 16.8 g (n = 543) Patients with sK values, n543543459395339sK, mEq/L5.70 ± 0.545.44 ± 0.565.41 ± 0.545.36 ± 0.555.40 ± 0.55sK < 5.5 mEq/L, %27.349.952.358.256.0 Drug strength of 25.2 g (n = 74) Patients with sK values, n7474645949sK, mEq/L5.74 ± 0.565.52 ± 0.545.45 ± 0.535.48 ± 0.665.53 ± 0.51sK < 5.5 mEq/L, %25.744.654.749.238.8 Table 5Serum potassium changes by drug strength among patients who were prescribed patiromer once a dayBaselineFollow-up–1Q; refQ1Q2Q3Q4 Drug strength of 8.4 g (n = 5452) Patients with serum potassium (sK) values, n54525447433436193070sK, mEq/L5.61 ± 0.555.31 ± 0.555.24 ± 0.555.24 ± 0.565.21 ± 0.55sK < 5.5 mEq/L, %34.762.367.066.870.1 Drug strength of 16.8 g (n = 543) Patients with sK values, n543543459395339sK, mEq/L5.70 ± 0.545.44 ± 0.565.41 ± 0.545.36 ± 0.555.40 ± 0.55sK < 5.5 mEq/L, %27.349.952.358.256.0 Drug strength of 25.2 g (n = 74) Patients with sK values, n7474645949sK, mEq/L5.74 ± 0.565.52 ± 0.545.45 ± 0.535.48 ± 0.665.53 ± 0.51sK < 5.5 mEq/L, %25.744.654.749.238.8 Serum potassium changes by drug strength among patients who were prescribed patiromer once a day Subgroup analyses Subgroup analyses demonstrated consistent longitudinal reductions in serum potassium after patiromer initiation across clinically relevant patient groups defined by patiromer strength, treatment schedule, baseline potassium levels, RAAS inhibitor use, and CHF status. Details were presented in Supplemental Tables 2–6. Discussion This large, retrospective cohort study of 10,860 adult HD patients described longitudinal serum potassium trends and patiromer utilization patterns in routine clinical practice. Across the study population, lower mean sK levels were observed following patiromer initiation, along with a decline in the use of 1 K baths compared to baseline, while serum electrolyte concentrations remained stable. These patterns were sustained through the 12-month follow-up period and were consistently observed across multiple clinically relevant subgroups. The reduction in mean sK levels observed is consistent with findings from previous clinical trials that led to approval of patiromer for the treatment of hyperkalemia [12, 13]. In contrast to trials conducted in earlier stages of CKD, this study examined patients with ESRD receiving maintenance HD, where available clinical evidence is comparatively limited [18]. A randomized, open-label trial with 33 ESRD patients treated with HD thrice weekly showed that participants who received patiromer had a lower median number of hyperkalemic events compared to those receiving usual care [14]. Additionally, a Phase 2 trial of 6 hyperkalemic HD patients found that daily administration of patiromer led to a reduction in mean sK levels [15]. Although clinical trial evidence on the use of patiromer in HD patients is limited, real-world studies and case studies have similarly described reductions in sK levels with patiromer treatment in this population [16, 19–21]. Furthermore, a US-based retrospective cohort study from 2015 to 2016 found that patiromer lowered mean sK by an average 0.5 mEq/L among 527 HD patients, and that there was a 50% relative reduction in the proportion of patients with severe hyperkalemia after patiromer initiation [17]. Our study also provides insights into treatment schedules in the HD population, reflecting how patiromer is being utilized in clinical practice. When stratified by treatment schedule, reductions in mean sK were observed across all groups following patiromer initiation; however, the single-dose group showed the smallest reductions in mean sK and prescriptions of at least one 1 K bath. The smaller magnitude of change observed in the single-dose group may be attributable to the lower baseline sK level (4.91 mEq/L), the small sample size of this group (n = 238), and the limited therapeutic exposure associated with a single administered dose. The distribution of treatment schedules observed in our study is consistent with prior real-world analyses, with once-a day-dosing representing the most frequently prescribed patiromer schedule [17]. When stratified by dosage strength, larger reductions in mean sK were observed in the 8.4 g and 16.8 g doses relative to the 25.2 g dose. Although the reduction in sK was smaller with the 25.2 g dose, serum electrolyte levels remained relatively stable. Notably, the percentage of patients prescribed at least one 1 K bath was increased above baseline in Q1 and Q2 for the 25.2 g dosing group, before decreasing below baseline in Q3 and Q4. Interpretation of findings in this group is limited, as the small sample size of the treatment group (n = 109) limits the strength of interpretation, and further data is required to make conclusions. The 8.4 g dose was the most commonly prescribed in our study, which is consistent with prior real-world analyses reporting it as the most frequently used dose in clinical practice [19, 20]. Finally, the number of patients up-titrated or down-titrated was comparable to previous analyses with approximately 89% of patients maintaining their initial dosage throughout the study period [16, 17]. Notably, this indicates that most patients did not require dose modification over time. In addition to reductions in sK, our study found a decline in the proportion of patients prescribed 1 K dialysate baths. This trend was observed in the overall population and across multiple subgroups. While low-potassium dialysate can aid in managing hyperkalemia, it has also been associated with rapid sK shifts, which may increase the risk of arrhythmias and sudden cardiac death, particularly following the long interdialytic interval [22–24]. The interdialytic interval, especially the two-day gap, has been shown to carry heightened risk of both hyperkalemia and mortality among patients receiving maintenance HD [4, 25, 26]. This was consistent with our study, which found that fluid-related and hyperkalemia hospital admissions were most common following the long interdialytic interval on Sunday and Monday. Although reductions in hyperkalemia-related hospitalizations were observed, these findings should be interpreted cautiously, as time-varying covariates were not controlled in the models and hospitalization trends may be influenced by secular changes in care, survivor bias, indication bias, and unmeasured confounding. Subgroup analyses based on baseline sK, RAASi use, and CHF status provide additional descriptive insight into the clinical benefits of patiromer in HD patients. Patients with higher baseline sK experienced greater absolute reductions in potassium levels, and were also more likely to be prescribed slightly higher patiromer doses, reflecting individualized dose titration in routine clinical practice. Among patients on RAASi therapy, reductions in sK were also observed following patiromer initiation, reinforcing its potential role in enabling continued use of RAASi in patients with impaired renal function. Similarly, patients with comorbid CHF demonstrated sK reductions comparable to those without CHF, supporting its use in a population at high risk of volume overload and arrhythmias. Together, these findings highlight the versatility of patiromer across diverse clinical scenarios commonly encountered in dialysis care. This study has several limitations to consider. As a retrospective, single-arm observational analysis of secondary data, it is subject to inherent residual confounding and potential biases that cannot be fully accounted for. Furthermore, the observational and descriptive nature of the study limits the ability to draw definitive conclusions regarding causality. Importantly, the absence of a comparator group limits the ability to attribute observed changes in potassium levels, dialysate prescriptions, or hospitalization rates to patiromer use. Changes over time may reflect underlying clinical trends, regression to the mean, or other concurrent interventions. Additionally, hospitalization outcomes did not adjust time-varying covariates and may be influenced by survivor bias, indication bias, and unmeasured confounding. Besides, a direct mechanistic link between patiromer use and volume overload–related hospitalizations cannot be established in this observational study, as such outcomes may be influenced by multifactorial clinical and dialysis-related factors rather than potassium-binding therapy alone. Patiromer use was assessed based on prescription records; however, information on patient adherence was not available. Additionally, information on the reasons for treatment initiation, dose adjustments, or discontinuations was not available, thus limiting the ability to fully characterize the clinical context in which treatment decisions were made. Furthermore, data on side effects were not captured, limiting the ability to fully assess the safety profile of patiromer in this population. Attrition over the 12-month follow-up period was gradual, and decreased sample size over time may have influenced longitudinal estimates. Despite these limitations, the study’s strengths include its large, unselected HD population and the breadth of subgroup analyses conducted, offering valuable real-world insights into patiromer use across a diverse patient population. In this large, real-world cohort of adult patients receiving maintenance HD, patiromer initiation was followed by reductions in mean sK levels and decreased use of 1 K dialysate baths, while serum electrolyte concentrations remained stable. These patterns were sustained over a 12-month period and were consistently observed across multiple clinically relevant subgroups, including those defined by treatment schedule, dosage strength, baseline potassium levels, and RAASi use. These findings help address gaps in the literature on patiromer use in the HD population, where randomized trial data are limited, and support its real-world utility and safety in managing hyperkalemia. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1